2021
Automated digital TIL analysis (ADTA) adds prognostic value to standard assessment of depth and ulceration in primary melanoma
Moore MR, Friesner ID, Rizk EM, Fullerton BT, Mondal M, Trager MH, Mendelson K, Chikeka I, Kurc T, Gupta R, Rohr BR, Robinson EJ, Acs B, Chang R, Kluger H, Taback B, Geskin LJ, Horst B, Gardner K, Niedt G, Celebi JT, Gartrell-Corrado RD, Messina J, Ferringer T, Rimm DL, Saltz J, Wang J, Vanguri R, Saenger YM. Automated digital TIL analysis (ADTA) adds prognostic value to standard assessment of depth and ulceration in primary melanoma. Scientific Reports 2021, 11: 2809. PMID: 33531581, PMCID: PMC7854647, DOI: 10.1038/s41598-021-82305-1.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiopsyChemotherapy, AdjuvantClinical Decision-MakingDeep LearningFemaleFollow-Up StudiesHumansImage Processing, Computer-AssistedKaplan-Meier EstimateLymphocytes, Tumor-InfiltratingMaleMelanomaMiddle AgedNeoplasm StagingPatient SelectionPrognosisRetrospective StudiesRisk AssessmentROC CurveSkinSkin NeoplasmsYoung AdultConceptsTumor-infiltrating lymphocytesDisease-specific survivalEarly-stage melanomaOpen-source deep learningCutoff valueMultivariable Cox proportional hazards analysisCox proportional hazards analysisDeep learningLow-risk patientsProportional hazards analysisKaplan-Meier analysisAccurate prognostic biomarkersEosin imagesAccuracy of predictionAdjuvant therapyRisk patientsSpecific survivalPrognostic valueValidation cohortReceiver operating curvesTraining cohortTIL analysisClinical trialsPrimary melanomaPrognostic biomarkerUsing Machine Learning Algorithms to Predict Immunotherapy Response in Patients with Advanced Melanoma
Johannet P, Coudray N, Donnelly DM, Jour G, Illa-Bochaca I, Xia Y, Johnson DB, Wheless L, Patrinely JR, Nomikou S, Rimm DL, Pavlick AC, Weber JS, Zhong J, Tsirigos A, Osman I. Using Machine Learning Algorithms to Predict Immunotherapy Response in Patients with Advanced Melanoma. Clinical Cancer Research 2021, 27: 131-140. PMID: 33208341, PMCID: PMC7785656, DOI: 10.1158/1078-0432.ccr-20-2415.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedDisease ProgressionDrug Resistance, NeoplasmFemaleFollow-Up StudiesHumansImage Processing, Computer-AssistedImmune Checkpoint InhibitorsMachine LearningMaleMelanomaMiddle AgedNeoplasm StagingPrognosisProgression-Free SurvivalProspective StudiesRisk AssessmentROC CurveSkinSkin NeoplasmsConceptsProgression-free survivalImmune checkpoint inhibitorsLower riskClinicodemographic characteristicsAdvanced melanomaClinical dataWorse progression-free survivalICI treatment outcomesKaplan-Meier curvesBiomarkers of responseStandard of careCheckpoint inhibitorsICI responseImmunotherapy responseValidation cohortTraining cohortDisease progressionProspective validationTreatment outcomesHigh riskClinical practicePatientsROC curveProgressionRisk
2015
Development and Clinical Validation of an In Situ Biopsy-Based Multimarker Assay for Risk Stratification in Prostate Cancer
Blume-Jensen P, Berman DM, Rimm DL, Shipitsin M, Putzi M, Nifong TP, Small C, Choudhury S, Capela T, Coupal L, Ernst C, Hurley A, Kaprelyants A, Chang H, Giladi E, Nardone J, Dunyak J, Loda M, Klein EA, Magi-Galluzzi C, Latour M, Epstein JI, Kantoff P, Saad F. Development and Clinical Validation of an In Situ Biopsy-Based Multimarker Assay for Risk Stratification in Prostate Cancer. Clinical Cancer Research 2015, 21: 2591-2600. PMID: 25733599, DOI: 10.1158/1078-0432.ccr-14-2603.Peer-Reviewed Original ResearchConceptsBiomarker risk scoreRisk scoreRisk groupsPredictive valueNational Comprehensive Cancer NetworkComprehensive Cancer NetworkCurrent risk stratification systemsIndependent prognostic informationRisk stratification systemProstate cancer aggressivenessRisk classification groupsAccurate risk predictionCoprimary endpointsFavorable pathologyAppropriate therapyCurative therapyRisk stratificationPathologic parametersPrognostic informationProstate biopsyProstate pathologyProstate cancerBlinded studyProstatectomy specimensCancer Network
2012
Stathmin expression and its relationship to microtubule‐associated protein tau and outcome in breast cancer
Baquero MT, Hanna JA, Neumeister V, Cheng H, Molinaro AM, Harris LN, Rimm DL. Stathmin expression and its relationship to microtubule‐associated protein tau and outcome in breast cancer. Cancer 2012, 118: 4660-4669. PMID: 22359235, PMCID: PMC3391341, DOI: 10.1002/cncr.27453.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAnalysis of VarianceBiomarkers, TumorBlotting, WesternBreastBreast NeoplasmsCell Line, TumorCohort StudiesFemaleFluorescent Antibody TechniqueGene Expression Regulation, NeoplasticHumansImmunohistochemistryKaplan-Meier EstimateLymphatic MetastasisMiddle AgedNeoplasm GradingNeoplasm StagingOdds RatioPredictive Value of TestsPrognosisProportional Hazards ModelsRisk AssessmentRisk FactorsRNA, Small InterferingStathminTau ProteinsTissue Array AnalysisTreatment OutcomeConceptsHigh stathmin expressionDisease-free survivalMAP-tauOverall survivalStathmin expressionBreast cancerHuman epidermal growth factor receptor 2 (HER2) expressionEpidermal growth factor receptor 2 expressionMultivariate analysisCox proportional hazards modelWorse overall survivalReceptor 2 expressionTissue microarray formatMicrotubule-associated protein tauProportional hazards modelBreast cancer cohortIndependent predictorsMenopausal statusNodal statusBetter prognosisPrognostic valueTumor sizePathological characteristicsProgesterone receptorNuclear grade
2010
High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology
Anagnostou VK, Lowery FJ, Zolota V, Tzelepi V, Gopinath A, Liceaga C, Panagopoulos N, Frangia K, Tanoue L, Boffa D, Gettinger S, Detterbeck F, Homer RJ, Dougenis D, Rimm DL, Syrigos KN. High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology. BMC Cancer 2010, 10: 186. PMID: 20459695, PMCID: PMC2875218, DOI: 10.1186/1471-2407-10-186.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAgedBiomarkers, TumorCarcinoma, Large CellCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellCell DifferentiationCohort StudiesConnecticutFemaleGreeceHumansKaplan-Meier EstimateLung NeoplasmsMaleMiddle AgedNeoplasm StagingPredictive Value of TestsProportional Hazards ModelsProto-Oncogene Proteins c-bcl-2Reproducibility of ResultsRetrospective StudiesRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeUp-RegulationConceptsNon-small cell lung cancer patientsCell lung cancer patientsNon-squamous tumorsLung cancer patientsBcl-2 expressionNSCLC patientsCancer patientsBcl-2Favorable outcomeIndependent cohortSmall cell lung cancer patientsIndependent lower riskNon-squamous histologySubgroup of patientsHigh expressersSquamous cell carcinomaHigh Bcl-2 expressionBcl-2 protein levelsSquamous histologyMedian survivalPrognostic factorsValidation cohortCell carcinomaPathological characteristicsPrognostic stratification
2007
Quantitative Measurement of Epidermal Growth Factor Receptor Is a Negative Predictive Factor for Tamoxifen Response in Hormone Receptor–Positive Premenopausal Breast Cancer
Giltnane JM, Rydén L, Cregger M, Bendahl PO, Jirström K, Rimm DL. Quantitative Measurement of Epidermal Growth Factor Receptor Is a Negative Predictive Factor for Tamoxifen Response in Hormone Receptor–Positive Premenopausal Breast Cancer. Journal Of Clinical Oncology 2007, 25: 3007-3014. PMID: 17634479, DOI: 10.1200/jco.2006.08.9938.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBiomarkersBiopsy, NeedleBreast NeoplasmsDrug Resistance, NeoplasmErbB ReceptorsEstrogen AntagonistsFemaleHumansImmunohistochemistryMiddle AgedMultivariate AnalysisPredictive Value of TestsPremenopauseProbabilityProportional Hazards ModelsReceptors, EstrogenRisk AssessmentSensitivity and SpecificitySurvival AnalysisTamoxifenConceptsEpidermal growth factor receptorER-positive patientsEGFR expressionBreast cancerEstrogen receptorTamoxifen-treated patientsEarly breast cancerRecurrence-free survivalRandomized clinical trialsLow EGFR expressionSignificant beneficial effectAdjuvant tamoxifenGrowth factor receptorEndocrine therapyTamoxifen responseTamoxifen treatmentClinical trialsSitu protein expressionUntreated groupTissue microarrayPatientsBeneficial effectsProtein expressionFactor receptorTreatment effects